Hexamethylene bisacetamide

Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice^{[1][2][3][4][5]}. In Vitro:Hexamethylene bisacetamide (2.5-10 mM; 15 days) significantly inhibits the proliferation of SHG-44 cells in a dose-dependent manner, but the inhibitory effect is reversible^[2].
Hexamethylene bisacetamide (5-10 mM; 15 days) changes the morphology of SHG-44 cells and increases the degree of cell differentiation^[2].
Hexamethylene bisacetamide (1-20 mM; 30-480 minutes) inhibits the activation of MAPK, Akt signaling pathways and NF - κB in TNFα-treated A549 cells^[3].
Hexamethylene bisacetamide (5 mM; 2 h-7 days) induces apoptosis through Notch1, Bcl - 2 and p53 signaling pathways in Molt4 cells^[4].
Hexamethylene bisacetamide (0.1 mM; 2 h) regulates the expression of neuropeptides through MYH9 and ACTG1 in hypothalamic cells^[5]. In Vivo:Hexamethylene bisacetamide (1000 mg/kg intraperitoneal injection; 500-1000 mg/kg intravenous injection; 400 nmoles 2 μL intracerebroventricular injection; 7 days) has an improved effect in mouse obesity model^[5].